How are Substance Use Disorder Treatment Programs Adjusting to Value-Based Payment? A Statewide Qualitative Study.
Value-based payment
qualitative research
substance use disorder
Journal
Substance abuse : research and treatment
ISSN: 1178-2218
Titre abrégé: Subst Abuse
Pays: United States
ID NLM: 101514834
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
04
2020
accepted:
08
04
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
Healthcare systems are implementing value-based payment (VBP) arrangements in efforts to incentivize cost-effective, high quality of care. These arrangements represent a major shift for substance use disorder (SUD) treatment providers who may need to make changes to their clinical and business operations to meet new demands for quality under value-based contracts. This qualitative study was conducted in the context of New York State's efforts to implement VBP among SUD treatment providers to understand their experiences, challenges, and needs. Five focus groups were conducted across the State with a total of 68 treatment professionals. Content analysis was conducted and five themes emerged. First, competing demands, limited workforce and technology infrastructure, and perceived lack of information were leading to overwhelmed administrators. Second, confusion and financial fear was being driven by the need for new clinical roles, business practices, and external partnerships. Third, providers were undertaking a number of measures to address workforce needs. Fourth, providers were building new business models and clinical practices. Fifth, providers desired more support and information. As VBP models are being adopted, healthcare systems should identify ways to mitigate challenges and support SUD treatment providers that may have limited resources to address complex workforce, client, and infrastructure needs.
Identifiants
pubmed: 32518481
doi: 10.1177/1178221820924026
pii: 10.1177_1178221820924026
pmc: PMC7252360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178221820924026Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
J Subst Abuse Treat. 2014 Feb;46(2):158-64
pubmed: 24074851
Health Aff (Millwood). 2015 May;34(5):828-35
pubmed: 25941285
J Psychoactive Drugs. 2012 Apr-Jun;44(2):107-18
pubmed: 22880538
Med Care Res Rev. 2020 Dec;77(6):511-537
pubmed: 31216945
Psychiatr Clin North Am. 2012 Jun;35(2):327-56
pubmed: 22640759
Health Aff (Millwood). 2011 Aug;30(8):1402-10
pubmed: 21821557
J Subst Abuse Treat. 2006 Oct;31(3):221-33
pubmed: 16996385
Am J Public Health. 2019 Jun;109(6):885-891
pubmed: 30998407
Drug Alcohol Depend. 2007 May 11;88(2-3):138-45
pubmed: 17129680
J Psychoactive Drugs. 2017 Apr-Jun;49(2):151-159
pubmed: 28350232
J Subst Abuse Treat. 2016 Oct;69:9-18
pubmed: 27568505
JAMA. 2012 Apr 11;307(14):1513-6
pubmed: 22419800
Addiction. 2017 Jan;112(1):124-133
pubmed: 27517740
Health Aff (Millwood). 2016 Jun 1;35(6):1000-8
pubmed: 27269015
Afr J Emerg Med. 2017 Sep;7(3):93-99
pubmed: 30456117
Issue Brief (Commonw Fund). ;2017:1-15
pubmed: 29072894
Subst Abuse Treat Prev Policy. 2012 May 02;7:16
pubmed: 22551101